Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Immunovant Inc’s stock clocked out at $22.71, up 3.13% from its previous closing price of $22.02. In other words, the price has increased by $3.13 from its previous closing price. On the day, 1.04 million shares were traded. IMVT stock price reached its highest trading level at $23.06 during the session, while it also had its lowest trading level at $22.1.
Ratios:
To gain a deeper understanding of IMVT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.07 and its Current Ratio is at 9.07. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on October 14, 2025, initiated with a Hold rating and assigned the stock a target price of $16.
On March 03, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $20.Jefferies initiated its Hold rating on March 03, 2025, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Fromkin Andrew J. sold 22,249 shares for $23.25 per share. The transaction valued at 517,189 led to the insider holds 85,852 shares of the business.
Hughes Douglas J. sold 15,000 shares of IMVT for $348,665 on Dec 01 ’25. The Director now owns 120,773 shares after completing the transaction at $23.24 per share. On Dec 01 ’25, another insider, ANDREW J FROMKIN, who serves as the Director of the company, bought 22,249 shares for $24.15 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 3980529664 and an Enterprise Value of 3458659840.
Stock Price History:
The Beta on a monthly basis for IMVT is 0.59, which has changed by -0.22464788 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, IMVT has reached a high of $29.49, while it has fallen to a 52-week low of $12.72. The 50-Day Moving Average of the stock is 10.89%, while the 200-Day Moving Average is calculated to be 30.45%.
Shares Statistics:
It appears that IMVT traded 1.78M shares on average per day over the past three months and 1226610 shares per day over the past ten days. A total of 174.53M shares are outstanding, with a floating share count of 74.15M. Insiders hold about 57.70% of the company’s shares, while institutions hold 54.83% stake in the company. Shares short for IMVT as of 1763078400 were 16381611 with a Short Ratio of 9.21, compared to 1760486400 on 17009989. Therefore, it implies a Short% of Shares Outstanding of 16381611 and a Short% of Float of 26.97.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 10.0 analysts currently analyzing and rating the stock of Immunovant Inc (IMVT).The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.57 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$2.54 and -$3.34 for the fiscal current year, implying an average EPS of -$2.97. EPS for the following year is -$3.0, with 11.0 analysts recommending between -$1.96 and -$3.98.
